Walsopan 40mg Tablet contains Pantoprazole, a proton pump inhibitor (PPI) that effectively reduces gastric acid secretion by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. It is primarily indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and other conditions associated with excessive stomach acid production. Pantoprazole provides symptomatic relief from heartburn, acid regurgitation, and promotes healing of acid-related mucosal damage. The 40mg dosage is commonly prescribed for adults and is administered orally, typically once daily before meals. Walsopan is well-tolerated, with a favorable safety profile; however, potential adverse effects may include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use should be monitored due to possible risks such as vitamin B12 deficiency, hypomagnesemia, and increased susceptibility to gastrointestinal infections. It is contraindicated in patients with known hypersensitivity to pantoprazole or other PPIs. Caution is advised when co-administered with drugs dependent on gastric pH for absorption or metabolized via the cytochrome P450 system. Walsopan 40mg Tablet should be used under medical supervision, with adherence to prescribed dosage and duration to ensure optimal therapeutic outcomes and minimize adverse effects.